Adverse Drug Reactions Associated with CYP 2B6 Polymorphisms in HIV/AIDS-Treated Patients in Yaoundé, Cameroon

Figures & data

Table 1 Baseline Characteristics of the Study Population

Variables	Minimum	Maximum	Mean ± Std Deviation
Age (years)	19	64	37.50 ± 10.475
Weight (kg)	40	99	61.52 ± 10.41
Hemoglobin (g/dl)	4	19	10.82 ± 2.515
CD4 (cells/mm^3)	7	426	185.52 ± 105.23

Table 2 Distribution and Association of Adverse Drug Reactions with Baseline Characteristics

Variable	Adverse Drug Reactions		Total	p value
	Yes	No
Sex
Female	17	57	74	0.083
Male	18	30	48
Total	35	87	122
Age (years)
≤45	26	69	95	0.545
>45	9	18	27
Total	35	87	122
Weight (kg)
≤50	6	15	21	0.989
>50	29	72	101
Total	35	87	122
CD4 (cells/mm^3)
≤200	17	50	67	0.371
>200	18	37	55
Total	35	87	122
Hemoglobin (g/dl)
≤10	13	34	47	0.842
>10	22	53	75
Total	35	87	122

Figure 1 Genotype frequencies for the CYP2B6 516G>T SNP in the study population.

Abbreviations: GG, Extensive Metabolizer; GT, Intermediate Metabolizer; TT, Slow metabolizer.

Figure 2 Genotype frequencies for the CYP2B6 983T>C SNP in the study population.

Abbreviations: TT, Extensive Metabolizer; CT, Intermediate Metabolizer; CC, Slow metabolizer.

Table 3 Association Between CYP2B6 516G>T SNP and CYP2B6 983T>C SNP Genotype/Phenotype of Participants with or Without ADR

SNP	Genotype	Adverse Drug Reactions		OR [95% CI]	p value
		Yes: n (%)	No: n (%)
516 G>T	GG (EM)	0 (0)	10 (11.50)	0.885 [0.821–0.955]	0.029*
	GT (IM)	24 (68.57)	55 (63.22)	1.208 [0.523–2.791]	0.416
	TT(SM)	11 (31.43)	22 (25.28)	1.354 [0.572–3.206]	0.317
	Total	35 (100)	87 (100)
T>C	TT (EM)	31 (88.57)	78 (89.65)	0.894 [0.256–3.119]	0.544
	TC (IM)	0 (0)	5 (5.75)	0.943 [0.895–0.993]	0.178
	CC (SM)	4 (11.43)	4 (4.60)	2.677 [0.631–11.369]	0.164
	Total	35 (100)	87 (100)

Note: *Statistically significant p value.

Abbreviations: SNP, Single Nucleotide Polymorphism; OR, Odds Ratio; CI, Confidence Interval; EM, Extensive Metabolizer; IM, Intermediate Metabolizer; SM, Slow metabolizer; n, number; %, percentage.

Table 4 Different Haplotypes and Their Prevalence in the Study Population

Haplotypes	Number	Frequency (%)
516GG/983TT	9	7.38
516GG/983CT	1	0.82
516GG/983CC	0	0
516GT/983TT	71	58.20
516GT/983CT	3	2.46
516GT/983CC	6	4.92
516TT/983TT	29	23.77
516TT/983CT	1	0.82
516TT/983CC	2	1.64
Total	122	100%